Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Incorrect Figure

Incorrect Figure Letters Conflict of Interest Disclosures: Dr Locatelli reported speakers’ bureau and/or advisory board membership for Amgen, Novartis, Bellicum Pharmaceuticals, Guidelines for Letters Miltenyi, Jazz Pharmaceuticals, Takeda, Neovii, and Medac. Dr Zugmaier reported receiving personal fees from Amgen, issue of patents (20190300609, Letters discussing a recent JAMA article should be submitted within 4 20130323247, and 20110262440), and having patents pending (10696744, weeks of the article's publication in print. Letters received after 4 weeks 10662243, 20190142846, 20190142846, 20170327581, 10130638, 9688760, will rarely be considered. Letters should not exceed 400 words of text 20170122947, 9486475, 20160208001, 9192665, 20150071928, 8840888, 20140228316, 20140227272, 20130287778, and 20130287774). and 5 references and may have no more than 3 authors. Letters report- Dr von Stackelberg reported advisory board membership for Amgen, Novartis, ing original research should not exceed 600 words of text and 6 refer- MorphoSys, Jazz Pharmaceuticals, and Shire. ences and may have no more than 7 authors. They may include up to 2 1. Duell J, Dittrich M, Bedke T, et al. Frequency of regulatory T cells determines tables or figures but online supplementary material is not allowed. All the outcome of the T-cell-engaging antibody blinatumomab in patients letters should include a word count. Letters http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Incorrect Figure

JAMA , Volume 326 (4) – Jul 27, 2021

Incorrect Figure

Abstract

Letters Conflict of Interest Disclosures: Dr Locatelli reported speakers’ bureau and/or advisory board membership for Amgen, Novartis, Bellicum Pharmaceuticals, Guidelines for Letters Miltenyi, Jazz Pharmaceuticals, Takeda, Neovii, and Medac. Dr Zugmaier reported receiving personal fees from Amgen, issue of patents (20190300609, Letters discussing a recent JAMA article should be submitted within 4 20130323247, and 20110262440), and having patents pending (10696744, weeks of the...
Loading next page...
 
/lp/american-medical-association/incorrect-figure-7ic8wuT6JK
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.9741
Publisher site
See Article on Publisher Site

Abstract

Letters Conflict of Interest Disclosures: Dr Locatelli reported speakers’ bureau and/or advisory board membership for Amgen, Novartis, Bellicum Pharmaceuticals, Guidelines for Letters Miltenyi, Jazz Pharmaceuticals, Takeda, Neovii, and Medac. Dr Zugmaier reported receiving personal fees from Amgen, issue of patents (20190300609, Letters discussing a recent JAMA article should be submitted within 4 20130323247, and 20110262440), and having patents pending (10696744, weeks of the article's publication in print. Letters received after 4 weeks 10662243, 20190142846, 20190142846, 20170327581, 10130638, 9688760, will rarely be considered. Letters should not exceed 400 words of text 20170122947, 9486475, 20160208001, 9192665, 20150071928, 8840888, 20140228316, 20140227272, 20130287778, and 20130287774). and 5 references and may have no more than 3 authors. Letters report- Dr von Stackelberg reported advisory board membership for Amgen, Novartis, ing original research should not exceed 600 words of text and 6 refer- MorphoSys, Jazz Pharmaceuticals, and Shire. ences and may have no more than 7 authors. They may include up to 2 1. Duell J, Dittrich M, Bedke T, et al. Frequency of regulatory T cells determines tables or figures but online supplementary material is not allowed. All the outcome of the T-cell-engaging antibody blinatumomab in patients letters should include a word count. Letters

Journal

JAMAAmerican Medical Association

Published: Jul 27, 2021

References